BLOOMFIELD, N.J., Sept. 27 /PRNewswire-FirstCall/ -- Alfacell Corporation
(Nasdaq: ACEL) today announced that Kuslima ("Tina") Shogen, Chairman and
Chief Executive Officer, was selected as one of the healthcare industry's 100
Most Inspiring People in a special issue of PharmaVOICE, a leading monthly
trade publication.
The PharmaVOICE 100 "represents a broad cross-section of industry sectors
- pharmaceutical, biotechnology, contract research, clinical trials, research
and development, patient education, patient recruitment, advertising,
technology, and many others," according to the publication.
Recipients profiled for the PharmaVOICE 100 were described as having a
"passion for the industry, the work they do, their colleagues, and most
importantly, the people who are impacted by what they bring to the table.
Their focus is clear: improving the discovery, development, access, and
understanding of life-improving and life-saving medications. Their passion is
felt by all those whose lives they touch. They've made a concerted effort to
put a more human face on the lifesciences industry. They have a personal
management style that stresses integrity, decency, and character."
Shogen was one of 27 individuals profiled in the 'Commanders and Chiefs'
section of the list, inclusive of "top-level executives at the forefront,
leading change within the industry and guiding their companies to success."
"I am truly honored to have been named to the PharmaVOICE 100," stated
Shogen. "To be acknowledged by my peers as worthy of such a prestigious honor
is humbling." Shogen concluded, "Being a part of this industry is a reward
unto itself. There are few other endeavors in life more satisfying than
advancing science for the greater good. I, along with my dedicated
colleagues, look forward to continuing to develop Alfacell's technology into
new and better medicines with passion and purpose."
For more information about the PharmaVOICE 100, visit http://www.pharmavoice.com.
About Alfacell Corporation
Alfacell Corporation is a biopharmaceutical company focused on the
discovery, development and commercialization of novel therapeutics for cancer,
using its proprietary ribonuclease (RNase) technology platform. ONCONASE(R)
(ranpirnase), Alfacell's lead investigational drug candidate, has been
successfully administered to over 850 patients with a variety of solid tumors,
and is currently being evaluated in a Phase IIIb trial for malignant
mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer
(NSCLC). For more information, please visit http://www.alfacell.com.
This press release includes statements that may constitute "forward-
looking" statements, usually containing the words "believe," "estimate,"
"project," "expect" or similar expressions. Forward-looking statements involve
risks and uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or contribute to
such differences include, but are not limited to, uncertainties involved in
transitioning from concept to product, uncertainties involving the ability of
the Company to finance research and development activities, potential
challenges to or violations of patents, uncertainties regarding the outcome of
clinical trials, the Company's ability to secure necessary approvals from
regulatory agencies, dependence upon third-party vendors, and other risks
discussed in the Company's periodic filings with the Securities and Exchange
Commission. By making these forward-looking statements, the Company undertakes
no obligation to update these statements for revisions or changes after the
date of this release.
Contact:
Alfacell Corporation: Investor/Media Relations:
Kuslima Shogen Elite Financial Communications
Robert Love Stephanie Noiseux
(973) 748-8082 (407) 585-1080
info@alfacell.com acel@efcg.net
SOURCE Alfacell Corporation
 back to top
Related links:
http://www.alfacell.com
http:/www.pharmavoice.com
CONTACT:
Kuslima Shogen or Robert Love of Alfacell
Corporation, +1-973-748-8082, info@alfacell.com; or Investor
Relations, Stephanie Noiseux of Elite Financial Communications,
+1-407-585-1080, acel@efcg.net, for Alfacell Corporation
|
